Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Source of water, electrolytes, and calories for parenteral nutrition,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis (via acetate/gluconate)
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Dextrose: <15 minutes (rapidly cleared from plasma); Electrolytes: No true half-life, as they are distributed and excreted according to homeostatic mechanisms.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, providing energy. Acetate and gluconate are metabolized primarily in the liver and skeletal muscle to bicarbonate. Electrolytes are not metabolized.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal: 90% (as water and electrolytes); Dextrose is metabolized to CO2 and water, with negligible renal excretion of unchanged drug.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Minimal (<5%) for electrolytes and dextrose; not significantly bound to plasma proteins.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Electrolytes: Vd of sodium ~0.6 L/kg (total body water); Dextrose: Vd ~0.2-0.3 L/kg (extracellular fluid); overall Vd approximates 0.6 L/kg.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Not applicable; drug is only administered intravenously (IV), so bioavailability is 100%.
Intravenous: 100%.
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²) due to risk of potassium and magnesium accumulation; for e GFR 30-59 m L/min/1.73 m², reduce infusion rate by 50% and monitor electrolytes; no adjustment for e GFR ≥ 60 m L/min/1.73 m².
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Child-Pugh Class A or B: no adjustment needed; Child-Pugh Class C: monitor serum magnesium and potassium closely due to reduced clearance; consider reduced infusion rate (e.g., 75% of normal) and frequent electrolyte monitoring.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Intravenous infusion; dose based on weight: infants: 100-150 m L/kg/day; children: 100-200 m L/kg/day; adjust for ongoing losses and serum glucose; not recommended for neonates due to risk of hyperkalemia; maximum infusion rate 2-5 m L/kg/hour depending on age and clinical status.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Elderly patients: use lower initial rates (e.g., 50-100 m L/hour) with careful monitoring of fluid overload, serum electrolytes, and glucose tolerance; due to age-related renal decline, consider dose reduction if e GFR < 60 m L/min/1.73 m²; avoid in patients with heart failure or significant renal impairment.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload.,Monitor serum glucose, electrolytes, and fluid status regularly.,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis.,Do not administer simultaneously with blood through the same infusion set (risk of hemolysis) unless using a Y-type connector with proper flushing.
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Severe hyperglycemia (e.g., diabetic ketoacidosis),Hyperkalemia,Severe renal impairment with oliguria or anuria,Hypersensitivity to any component
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No specific food interactions. Dietary potassium/magnesium intake should be monitored in patients receiving this solution to avoid electrolyte imbalance. Patients with diabetes should coordinate dextrose infusion with insulin and meal timing.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is negligible as the solution is designed to replace fluids and electrolytes. No teratogenic effects reported in animal studies or human data. Trimester-independent low risk, but use only if clearly needed.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Compatible with breastfeeding. Components (dextrose, electrolytes) are endogenous and present in breast milk. No known M/P ratio available as the solution is composed of substances normally present in milk. Excretion is not clinically relevant; no adverse effects expected.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No specific dose adjustments required. Pregnancy induces increased plasma volume (40-50%) and glomerular filtration rate (50-85%), but crystalloid solutions like Plasma-Lyte M and Dextrose 5% are dosed based on clinical need (fluid replacement, maintenance). Monitor for hyperglycemia due to dextrose; consider lower infusion rates in gestational diabetes or preeclampsia-related fluid sensitivity.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
PLASMA-LYTE M AND DEXTROSE 5% is a balanced isotonic crystalloid containing multiple electrolytes (Na 40, K 13, Mg 3, Cl 40, acetate 16, gluconate 20 m Eq/L) with 5% dextrose. It is used for maintenance fluid therapy, particularly in pediatric or geriatric patients, or when mild potassium/magnesium supplementation is needed. The dextrose provides ~170 kcal/L and helps prevent ketosis. Avoid in patients with hyperkalemia, hypermagnesemia, or anuria. Acetate and gluconate serve as bicarbonate precursors (acetate is rapidly metabolized; gluconate slower). Monitor serum glucose in diabetics or stress states. Compatible with most IV medications; check specific compatibility.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This intravenous solution contains sugar (dextrose) and electrolytes to maintain fluid balance and provide calories.,Tell your healthcare provider if you have diabetes, kidney problems, or heart disease.,Report any signs of fluid overload: swelling, shortness of breath, or rapid weight gain.,This solution may be given with other medications; inform your nurse of all medications you are taking.,You may experience a cold sensation at the IV site; this is usually temporary.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is neg. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.